In addition, we compared the target genes of approved/investigational drugs for MS and SS with common susceptibility genes and found that the target genes of glatiramer acetate and daclizumab were HLA-DRB1 and IL2RA, respectively. This evidence concerns the gene IL2RA and synovial sarcoma.